Agilent Technologies Inc. (A) Introduces Next-Generation Sequencing Cancer Research Panels
9/2/2014 2:00:23 PM
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today introduced ClearSeq AML, the first product in the ClearSeq line of next-generation cancer research panels, which targets 48 selected exons in 20 of the most commonly mutated genes found in acute myeloid leukemia.
Designed in collaboration with Dr. Robert Ohgami and Dr. Daniel Arber at the Stanford Department of Pathology, Stanford University, ClearSeq AML provides comprehensive coverage of mutations and enables swift progression of sample processing to analysis in less than 48 hours. The AML gene panel will be followed by the release of additional ClearSeq panels for cancer research throughout the coming months.
Help employers find you! Check out all the jobs and post your resume.
comments powered by